New drug combo shows promise for rare, aggressive uterine cancer

NCT ID NCT05147558

First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 31 times

Summary

This study tests whether combining two drugs, pembrolizumab and lenvatinib, can shrink tumors or slow cancer growth in people with advanced uterine or ovarian carcinosarcoma, a rare and aggressive cancer. About 40 participants will receive the treatment, and researchers will also look for blood markers that might predict how well the cancer responds. The goal is to find a more effective treatment option for this hard-to-treat cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UTERINE CARCINOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge (Limited protocol activities)

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (Limited protocol activities)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Monmouth (Limited protocol activities)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Limited protocol activities)

    Rockville Centre, New York, 11553, United States

  • Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Westchester (Limited protocol activities)

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.